Select publications

Ando M et al. Genetic polymorphisms in the phenobarbital-responsive enhancer module of the UDP-Glucuronosyltransferase (UGT) 1A1 gene and irinotecan toxicity in Japanese patients. Proc ASCO 2003;Abstract 496.

Arch-Ferrer JE et al. Genetic expression of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase and its clinical correlation in gastric adenocarcinoma. Proc ASCO 2003;Abstract 1101.

Iqbal S, Lenz HJ. Targeted therapy and pharmacogenomic programs. Cancer 2003;97(8 Suppl):2076-82. Abstract

Lenz HJ et al. A multivariate analysis of genetic markers for clinical response to 5-FU/oxaliplatin chemotherapy in advanced colorectal cancer. Proc ASCO 2002;Abstract 513.

Lenz HJ. Pharmacogenomics in colorectal cancer. Semin Oncol 2003;30(4 Suppl 15):47-53. Abstract

Marsh S, McLeod HL. Cancer pharmacogenetics. Br J Cancer 2004;90(1):8-11. Abstract

Park DJ et al. Tailoring chemotherapy in advanced colorectal cancer. Curr Opin Pharmacol 2003;3(4):378-85. Abstract

Wasserman E et al. Severe CPT-11 toxicity in patients with Gilbert’s syndrome: Two case reports. Ann Oncol 1997;8(10):1049-51. Abstract

Watters JW, McLeod HL. Cancer pharmacogenomics: Current and future applications. Biochim Biophys Acta 2003;1603(2):99-111. Abstract